Champions Oncology, Inc.CSBRNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P5
Near historical low
vs 5Y Ago
-1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q1 2026 | -13.19% |
| Q4 2025 | 25.65% |
| Q3 2025 | 6.06% |
| Q2 2025 | 14.19% |
| Q1 2025 | 1.78% |
| Q4 2024 | 16.16% |
| Q3 2024 | -29.04% |
| Q2 2024 | -6.27% |
| Q1 2024 | -13.08% |
| Q4 2023 | -9.95% |
| Q3 2023 | -2.07% |
| Q2 2023 | -10.93% |
| Q1 2023 | 22.96% |
| Q4 2022 | -9.80% |
| Q3 2022 | 11.47% |
| Q2 2022 | 18.75% |
| Q1 2022 | -5.13% |
| Q4 2021 | -0.22% |
| Q3 2021 | 11.30% |
| Q2 2021 | 10.16% |
| Q1 2021 | 13.88% |
| Q4 2020 | 3.32% |
| Q3 2020 | -12.20% |
| Q2 2020 | 30.77% |
| Q1 2020 | 3.73% |
| Q4 2019 | 2.92% |
| Q3 2019 | 4.41% |
| Q2 2019 | -1.65% |
| Q1 2019 | 6.37% |
| Q4 2018 | 9.65% |
| Q3 2018 | -0.55% |
| Q2 2018 | 4.69% |
| Q1 2018 | -6.28% |
| Q4 2017 | -0.27% |
| Q3 2017 | 3.90% |
| Q2 2017 | 7.82% |
| Q1 2017 | -0.99% |
| Q4 2016 | -16.76% |
| Q3 2016 | 2.98% |
| Q2 2016 | 17.72% |